share_log

Cathy Scangarella to Join the Advisory Board of Xcelerate, Inc.

Cathy Scangarella to Join the Advisory Board of Xcelerate, Inc.

凱西·斯坎加雷拉將加入Xcelerate,Inc.的顧問委員會。
Accesswire ·  2022/06/07 20:35

MAULDIN, SC / ACCESSWIRE / June 7, 2022 / Xcelerate, Inc. (OTC PINK:XCRT) today announced that Cathy Scangarella has accepted an invitation to join its Advisory Board effective immediately.

南卡羅來納州莫爾丁,ACCESSWIRE/2022年6月7日/Xcelerate,Inc.(場外交易市場代碼:XCRT)今天宣佈,Cathy Scangarella已接受邀請加入其顧問委員會,立即生效。

Cathy Scangarella is the Chief Business Development Officer and sector lead for Life Sciences at Choose New Jersey, New Jersey's leading nonprofit economic development organization. Cathy leads the business development team and oversees the organization's national and international lead generation, prospect management and business development strategy for all key industries. She also oversees the Choose New Jersey India and Europe offices and has enhanced New Jersey's relationships with key multipliers and trade associations around the globe.

凱西·斯坎加雷拉是新澤西州領先的非營利性經濟發展組織Choose New Jersey的首席業務發展官和生命科學部門負責人。凱西領導着業務開發團隊,並監督該組織針對所有關鍵行業的國內和國際領先地位產生、前景管理和業務發展戰略。她還負責管理Choose新澤西州、印度和歐洲辦事處,並加強了新澤西州與全球重要的倍增公司和貿易協會的關係。

During her tenure at Choose New Jersey, Cathy developed a new tactical business development approach for business attraction efforts to concentrate efforts in key domestic and international markets. She had a leading role in the strategic planning of Choose New Jersey's business attraction missions to Israel, Germany, Ireland, and India. While abroad, she helped established international university collaborations and industry partnerships for many of New Jersey's research universities including Rutgers University, Princeton University, New Jersey City University and Rowan University. Notable clients include Ascelia Pharma, BAP Pharma, CSL Plasma, Fordoz Pharmaceuticals, Minerva Biolabs and Biofarma US.

在新澤西州Choose任職期間,Cathy開發了一種新的戰術性業務發展方法,以吸引業務,將精力集中在關鍵的國內和國際市場。她在Choose New Jersey赴以色列、德國、愛爾蘭和印度的招商代表團的戰略規劃中發揮了領導作用。在國外期間,她幫助新澤西州的許多研究型大學建立了國際大學合作和行業合作伙伴關係,包括羅格斯大學、普林斯頓大學、新澤西城市大學和羅文大學。著名客户包括Ascelia Pharma、BAP Pharma、CSL等離子體、Fordoz製藥公司、Minerva Biolabs和Biofarma US。

Cathy is a veteran of New Jersey State government, having served six administrations. With over 25 years of experience in marketing, outreach, and business development, she has served as Deputy Chief of Staff to Lt. Governor Guadagno, Director of State Marketing at the New Jersey Business Action Center, Director of Outreach Programs for Business Retention & Attraction at the New Jersey Economic Development Authority, and Vice President of Marketing & Communications for the New Jersey Commerce Commission. Cathy is a member of the Research With New Jersey Advisory Board, the Innovation New Jersey Coalition, and an E&Y Entrepreneur of the Year Judge 2019-2021. She was named among the ROI-NJ Influencers: Women in Business - Economic Development in 2021.

凱西是新澤西州政府的資深人士,曾在六屆政府任職。她在營銷、外聯和業務開發方面擁有超過25年的經驗,曾擔任過瓜達尼奧副州長的副幕僚長,新澤西州商業行動中心州市場營銷部的董事,新澤西州經濟發展局商業保留和吸引外聯計劃的董事,以及新澤西州商務委員會營銷和傳播部副總裁。凱西是新澤西研究諮詢委員會、新澤西創新聯盟的成員,也是2019-2021年安永年度企業家評委。她被提名為ROI-NJ影響力人物:2021年商業中的女性-經濟發展。

Cathy holds a Bachelor of Science degree in Business Administration with a concentration in Marketing from Ramapo College of New Jersey.

凱西擁有新澤西州拉馬波學院工商管理學士學位,主修市場營銷。

"Cathy brings a valued new skill set to our Advisory Board," said Michael O'Shea, Xcelerate's CEO. "Cathy's' experience business development, along with her years of relationships with research institutions, should prove invaluable to Xcelerate as we begin to advance the development of the portfolio of patents recently acquired from HS Pharmaceuticals as well as our continued development of patentable med-tech. "

Xcelerate的首席執行官Michael O‘Shea説:“Cathy為我們的顧問委員會帶來了一套寶貴的新技能。隨着我們開始推進最近從HS製藥公司收購的專利組合的發展,以及我們對可專利醫療技術的持續開發,凱西的業務發展經驗以及她與研究機構多年的關係將被證明對Xcelerate公司來説是無價的。“

"I would like to thank our partners and investors for their continued support as we continue to execute on our business plan"

我要感謝我們的合作伙伴和投資者在我們繼續執行我們的商業計劃時給予的持續支持。

For more information please contact info@xcelerate.global

欲瞭解更多信息,請聯繫info@xcelerate.global。

SAFE HARBOR

安全港

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.

本新聞稿可能包含經修訂的1934年證券交易法(“交易法”)第21E節所指的前瞻性信息,包括與公司、其董事或高級管理人員在以下方面的意圖、信念或當前預期有關的所有不是歷史事實的陳述:(1)公司的融資計劃;(2)影響公司財務狀況或經營結果的趨勢;(3)公司的增長戰略和經營戰略;以及(4)宣佈和支付股息。“可能”、“將”、“將”、“預期”、“估計”、“預期”、“相信”、“打算”以及類似的表述及其變體旨在識別前瞻性陳述。請投資者注意,任何此類前瞻性陳述都不是對未來業績的保證,涉及風險和不確定性,其中許多風險和不確定性超出了公司的控制能力,實際結果可能與前瞻性陳述中預測的結果大不相同 由以下原因導致 各種因素。

SOURCE: Xcelerate, Inc.

資料來源:Xcelerate公司


View source version on accesswire.com:
在accesswire.com上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論